Aurora Therapeutics
Aurora Therapeutics is a clinical-stage biotech developing personalized CRISPR gene editing therapies for rare genetic diseases, starting with phenylketonuria. Leveraging modular gene editors and the FDA's plausible mechanism pathway, the company is building a scalable platform to extend treatment to multiple rare mutations.
- Company typePrivate
- Founded2026
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Aurora Therapeutics does
Aurora Therapeutics is a clinical-stage biotechnology company developing personalized CRISPR-based gene editing therapies for rare genetic diseases. The company was founded in Cambridge, Massachusetts on January 9, 2026 by CRISPR pioneers Jennifer Doudna (co-inventor of CRISPR and Nobel Laureate) and Fyodor Urnov (Scientific Director of the Innovative Genomics Institute and leader of the Baby KJ customized CRISPR therapy), with $16 million in seed funding led by Menlo Ventures. Its lead therapeutic program targets phenylketonuria (PKU), a metabolic disorder caused by mutations in the PAH gene of which more than 1,200 distinct variants have been identified.
Aurora's core technology is a modular gene editing platform built around CRISPR gene editors that can be rapidly retargeted to specific mutations by swapping guide RNAs, augmented by AI-generated editor engineering. The company pairs this platform with an umbrella regulatory approach that groups multiple rare mutations within a single disease into unified development paths, leveraging the FDA's new 'plausible mechanism pathway,' which permits approval based on a single well-controlled clinical investigation supported by confirmatory evidence. Aurora also points to purpose-built clinical, manufacturing, and quality systems designed for parallel, mutation-specific development, and has recruited leadership with deep rare-disease experience including CEO Edward Kaye (former CEO of Sarepta and Stoke Therapeutics), CSO Thomas Wechsler, Head of Research Morgan Maeder (ex-Editas and Chroma Medicine), and Head of CMC David Litvak (ex-Editas and nChroma Bio).
Aurora is pre-revenue and does not yet have commercial products. Its go-to-market model is built around FDA approval pathways for personalized gene editing therapies for rare diseases, with eventual commercialization through traditional pharmaceutical channels in the United States. The company is venture-backed by Menlo Ventures, whose Principal Johnny Hu serves as Board Chair and Partner Greg Yap serves on the Board, and currently operates with 11-50 employees headquartered at 238 Main Street, Cambridge, MA.
Aurora Therapeutics firmographics
Firmographics- Name
- Aurora Therapeutics
- Legal name
- Aurora Therapeutics
- Website
- https://auroratherapeutics.io
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Aurora Therapeutics is a clinical-stage biotech developing personalized CRISPR gene editing therapies for rare genetic diseases, starting with phenylketonuria. Leveraging modular gene editors and the FDA's plausible mechanism pathway, the company is building a scalable platform to extend treatment to multiple rare mutations.
- Ownership category
- akta.pro rank
Aurora Therapeutics industry classification
Industry- Product category
- Gene Therapy / Gene Editing Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro industry
- Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)Gene Therapy for Rare/Monogenic Diseases
Keywords
Where Aurora Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Aurora Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Revenue model
- Gene Therapy Commercialization: Aurora plans to commercialize personalized gene editing therapies for rare genetic diseases through FDA approval pathways. The company is building a sustainable platform capable of moving from one-patient breakthroughs to population-scale treatments, with initial focus on phenylketonuria and expansion to additional rare mutations over time.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Aurora Therapeutics product offering
Product offeringCore offering
Aurora Therapeutics develops a scalable, modular CRISPR-based gene editing platform to create personalized therapies for rare genetic diseases. Its lead program targets phenylketonuria (PKU) by addressing multiple PAH gene mutations within a single development approach, with plans to expand to additional rare mutations. The platform combines modular gene editors, AI-generated editor engineering, and an umbrella regulatory framework leveraging the FDA's "plausible mechanism pathway" to advance multiple mutation-specific treatments in parallel.
Product overview
Aurora Therapeutics operates as a biotech company developing a scalable personalized gene editing platform for rare genetic diseases. The company's core offering consists of a modular gene editing platform that combines CRISPR technologies with umbrella regulatory pathways, enabling parallel development of multiple mutation-specific therapies. Their lead product is the PKU (phenylketonuria) program, which represents their first therapeutic application designed to target multiple genetic mutations of the disease using a single development approach.
Differentiator
Problem solved
Functional benefit
Products and services
- Aurora Gene Editing Platform A scalable platform for personalized gene editing that combines modular CRISPR gene editors with umbrella regulatory pathways, enabling the development of multiple mutation-specific therapies in parallel for rare genetic diseases. It is designed to permanently correct the underlying genetic cause of a disease with a single course of treatment.
- Phenylketonuria (PKU) Program Aurora's initial therapeutic program targeting phenylketonuria, a metabolic disorder caused by mutations in the PAH gene. The therapy is designed to address multiple PKU-causing mutations from the outset using CRISPR gene editing to permanently correct the underlying genetic cause, intended for patients with PKU who today face lifelong restrictive dietary management.
Quantifiable outcome
- Targeting multiple PKU-causing mutations from the outset with plans to expand to additional mutations over time
Companies that use Aurora Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Aurora Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Aurora Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights5 records
Aurora Therapeutics competitors and assessment
Company assessmentDirect peers
- Prime Medicine: Developer of prime editing, a precision gene-editing technology for rare and serious diseases. Comparable as a next-generation gene-editing platform company pursuing multiple mutation-specific programs.
- Verve Therapeutics: Gene-editing company focused on cardiovascular disease using in vivo base editing. Comparable as a clinical-stage CRISPR-adjacent gene-editing platform pursuing disease-modifying treatments.
- CRISPR Therapeutics: Clinical-stage CRISPR/Cas9 gene-editing company developing Casgevy and a pipeline of in vivo and ex vivo gene-edited therapies. Most directly comparable to Aurora as a fellow CRISPR-therapeutics developer pursuing rare and serious diseases.
- Beam Therapeutics: Pioneer in base editing, a next-generation CRISPR-adjacent gene-editing modality, pursuing rare diseases and hematology. Comparable as a gene-editing platform targeting rare mutations with a similar scientific pedigree.
- Intellia Therapeutics: Clinical-stage company developing in vivo and ex vivo CRISPR/Cas9 therapies. Aurora Board Chair Johnny Hu's earlier gene-editing work was licensed by Editas and Beam; Intellia is a relevant competitor in rare-disease gene editing.
- Editas Medicine: Gene-editing company developing CRISPR-based therapies for serious diseases; Aurora's Head of Research Morgan Maeder was an early scientist at Editas. Directly comparable platform play in CRISPR therapeutics with overlap in rare-disease focus.
Broad incumbents
- Sarepta Therapeutics: Commercial-stage leader in genetic medicines for Duchenne muscular dystrophy and rare neuromuscular diseases; Aurora CEO Ed Kaye is former Sarepta CEO. Comparable as a rare-disease genetic-medicine commercial benchmark and a potential strategic acquirer or partner.
- Stoke Therapeutics: Clinical-stage company developing antisense oligonucleotide medicines for severe genetic diseases; Aurora CEO Ed Kaye is also former Stoke CEO. Comparable as a rare-disease genetic-medicine platform with overlapping leadership.
Emerging players
- Tune Therapeutics: Epigenetic editing company co-founded by Fyodor Urnov. Relevant as an emerging gene/epigenetic-editing platform player connected to Aurora's founder and pursuing related rare-disease applications.
- nChroma Bio: Emerging in vivo gene-editing company; Aurora's Head of CMC David Litvak was previously Head of Technical Operations at nChroma. Comparable as a newer gene-editing platform with shared talent.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Aurora Therapeutics social profiles
Digital presenceAurora Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aurora Therapeutics leadership team
Management profileNumber of profiles
Profiles8 records
Aurora Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aurora Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aurora Therapeutics
What does Aurora Therapeutics do?
Aurora Therapeutics develops a scalable, modular CRISPR-based gene editing platform to create personalized therapies for rare genetic diseases. Its lead program targets phenylketonuria (PKU) by addressing multiple PAH gene mutations within a single development approach, with plans to expand to additional rare mutations. The platform combines modular gene editors, AI-generated editor engineering, and an umbrella regulatory framework leveraging the FDA's "plausible mechanism pathway" to advance multiple mutation-specific treatments in parallel.
Is Aurora Therapeutics a public or private company?
Aurora Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aurora Therapeutics founded?
Aurora Therapeutics was founded in 2026. It employs 11 to 50 people.
Where is Aurora Therapeutics based?
Aurora Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Aurora Therapeutics make money?
One revenue line is on record: gene Therapy Commercialization.
Who are Aurora Therapeutics's main competitors?
Direct peers on record are Prime Medicine, Verve Therapeutics, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics and Editas Medicine. Broad incumbents are Sarepta Therapeutics and Stoke Therapeutics. Emerging players are Tune Therapeutics and nChroma Bio.
Does Aurora Therapeutics have an API?
No public API is recorded for Aurora Therapeutics.
What industry is Aurora Therapeutics in?
Aurora Therapeutics's product category is Gene Therapy / Gene Editing Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714.